Nimacimab Plus Semaglutide Achieves Superior Weight Loss in Phase 2a Trial

A peripherally acting cannabinoid receptor 1 (搜索)搜索该靶点 antibody combined with semaglutide查看药品详情 demonstrated superior weight loss efficacy compared to semaglutide alone in adults with overweight or obesity, according to data from the CBeyond phase 2a trial presented at ObesityWeek.

The study enrolled 136 adults with overweight or obesity without diabetes (mean age 45.6 years; 84.6% women) who were randomly assigned to receive once-weekly 200 mg nimacimab查看药品详情 alone, placebo, 200 mg nimacimab plus semaglutide查看药品详情 2.4 mg, or semaglutide alone for 26 weeks, followed by a 13-week follow-up period.

Enhanced Weight Loss Efficacy

Adults receiving nimacimab查看药品详情 plus semaglutide查看药品详情 achieved significantly greater weight reduction at 26 weeks compared to those receiving semaglutide alone, with a mean difference of -2.95 percentage points (95% CI, -5.7 to -0.2; P = 0.0372) in intention-to-treat analysis.

The combination therapy also demonstrated superior body composition changes. From baseline to 26 weeks, the nimacimab查看药品详情 plus semaglutide查看药品详情 group achieved a 21.12% fat mass loss and 6.48% lean mass reduction, compared to 15.35% fat mass reduction and 5.68% decrease in lean mass with semaglutide alone. Notably, the proportion of weight loss attributed to lean mass was lower with the combination therapy at 24% versus 28% with semaglutide alone.

Waist circumference reduction was also more pronounced in the combination group, with an 11.28 cm decline compared to 7.61 cm decrease for semaglutide查看药品详情 alone (P = 0.0492).

Reduced Weight Regain

During the off-treatment follow-up period from 26 to 38 weeks, the nimacimab查看药品详情 plus semaglutide查看药品详情 group demonstrated significantly less weight regain at 18.1% compared to 49.8% for adults receiving semaglutide alone. "It appears as though the addition of the nimacimab slowed down the regain of body fat and body weight," said Louis J. Aronne, MD, the Sanford I. Weill Professor of Metabolic Research at Weill Cornell Medicine.

Differentiated Mechanism of Action

Nimacimab查看药品详情 represents a novel approach to cannabinoid receptor 1 (搜索)搜索该靶点 modulation, differing significantly from previously investigated agents. "Nimacimab is an antibody that is peripherally restricted," Aronne explained. "There's minimal penetration into the brain and compared to small molecules, the difference is quite significant. It's also a negative allosteric modulator, which makes it retain its potency even in the presence of competition."

This peripheral restriction addresses safety concerns that led to the discontinuation of earlier cannabinoid receptor 1 (搜索)搜索该靶点 inhibitors rimonabant查看药品详情 and taranabant查看药品详情, both of which were associated with increased risk for suicidality despite demonstrating at least 5% weight loss in 50% or more of participants in phase 2 or phase 3 trials.

Safety Profile

Adverse events were reported in 80.9% of study participants overall, with rates of 91.7% in the semaglutide查看药品详情 alone group, 82.5% in the nimacimab查看药品详情 alone group, 78.6% in the nimacimab plus semaglutide group, and 75% in the placebo group. The most common treatment-emergent adverse events were nausea (18.4%), dizziness (15.4%), injection site erythema (13.2%), and headache (10.3%).

Gastrointestinal adverse events were more common with semaglutide查看药品详情 than nimacimab查看药品详情, with nimacimab demonstrating similar rates to placebo. Psychiatric adverse events were rare, with two reported in the semaglutide alone group, one in the nimacimab alone group, and one in the placebo group. All psychiatric adverse events were mild or moderate in severity.

Future Development

The favorable safety profile may enable exploration of higher doses in future studies. "Further dose-ranging studies are needed to demonstrate the optimal dose of nimacimab查看药品详情 for both monotherapy and combination treatment," Aronne noted. Participants who completed the 26-week treatment period were invited to participate in an ongoing 26-week extension study.